Vivo Capital’s ArriVent BioPharma AVBP Stock Holding History
Bought
Maintained
Sold
Other funds holding AVBP
IAM
Vivo Capital's AVBP Position: Q3 2026 in Review
Vivo Capital increased its ArriVent BioPharma (AVBP) stake by 6.2% in Q3 2026, buying an estimated $3.22M and bringing the position to 1,787,104 shares worth $54.1M. The position accounts for 5.96% of the portfolio, ranked #4.
Vivo Capital first reported a position in AVBP in Q1 2026 and has held it in 3 quarters since. The position peaked at $58.4M in Q2 2026. 153 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.
- Vivo Capital held 1,787,104 shares of ArriVent BioPharma worth $54.1M as of Q3 2026.
- Vivo Capital bought 105,007 ArriVent BioPharma shares in Q3 2026, an estimated $3.22M.
- ArriVent BioPharma made up 5.96% of Vivo Capital's portfolio in Q3 2026, its #4 holding.
- Vivo Capital first reported a position in ArriVent BioPharma in Q1 2026 and has held it in 3 quarters since.
- Vivo Capital's ArriVent BioPharma position peaked at $58.4M in Q2 2026.
- 153 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.
Based on Vivo Capital's 13F filing for Q3 2026, filed 13 Nov 2026.